Details for Patent: 9,333,310
✉ Email this page to a colleague
Which drugs does patent 9,333,310 protect, and when does it expire?
Patent 9,333,310 protects INCRUSE ELLIPTA, ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in five NDAs.
Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has nineteen patent family members in seventeen countries.
Summary for Patent: 9,333,310
| Title: | Medicament dispenser |
| Abstract: | A sheet driver for use in a medicament dispenser with blister pockets includes: (a) a base, extending from the base, (b) a shaft defining a rotational axis; at the base, (c) a drive surface for receipt of drive to rotate the base about the rotational axis; about the shaft, (d) a torsion spring defining first and second spring legs; mounting about the shaft and the torsion spring for rotation about the rotational axis, and (e) a hub defining a hub surface for receipt of a sheet of the medicament carrier, the hub surface being adapted to provide an initial effective winding surface which provides uniform indexing of the medicament carrier. |
| Inventor(s): | Jones; Christopher John (Warwick, GB), May; James John (Warwick, GB), Lintell; Daniel Thomas De Sausmarez (Ware, GB), Palmer; Mark Gregory (Ware, GB), Tansley; Robert William (Bidford on Avon, GB) |
| Assignee: | Glaxo Group Limited (Brentford, Middlesex, GB) |
| Application Number: | 13/483,168 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,333,310
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-003 | May 12, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,333,310
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0418278.8 | Aug 16, 2004 |
International Family Members for US Patent 9,333,310
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005274296 | ⤷ Sign Up | |||
| Brazil | PI0514346 | ⤷ Sign Up | |||
| Canada | 2577248 | ⤷ Sign Up | |||
| China | 100528256 | ⤷ Sign Up | |||
| China | 101084030 | ⤷ Sign Up | |||
| Cyprus | 1117205 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
